Published in Medical Letter on the CDC and FDA, February 1st, 2004
According to a study from Lithuania, "To evaluate the immunogenicity and tolerability of Epaxal in infants and children, 30 infants (aged six to seven months) and 30 children (aged five to seven years) received a single intramuscular dose of the aluminum-free virosomal hepatitis A virus (HAV) vaccine Epaxal and a booster dose after 12 months. Anti-HAV antibody titers were measured at baseline (before injection), at 1 and 12 months after primary vaccination, and one month after the booster vaccination."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.